Not applicableNot Yet RecruitingNCT06324058What this trial is testingCryoablation Versus BCG Instillation Therapy for High-risk NMIBCWho this might be right forBladder Cancer Huashan Hospital 190
Large-scale testing (Phase 3)Looking for participantsNCT06696794What this trial is testingInvestigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC PatientsWho this might be right forNon-Muscle-Invasive Bladder Cancer (NMIBC) Shaogang Wang 180
Not applicableLooking for participantsNCT05123625What this trial is testingPrognostic Effect of Whether Doing PLND During RC for High-risk NMIBCWho this might be right forBladder Cancer The First Affiliated Hospital with Nanjing Medical University 200
Testing effectiveness (Phase 2)Looking for participantsNCT06770582What this trial is testingTesting the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialWho this might be right forNon-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial CarcinomaStage I Bladder Cancer AJCC v8 National Cancer Institute (NCI) 160
Large-scale testing (Phase 3)Study completedNCT00406068What this trial is testingMycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder CancerWho this might be right forBladder Neoplasms Bioniche Life Sciences Inc. 129
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07356791What this trial is testingPhase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and SafetyWho this might be right forBladder (Urothelial, Transitional Cell) Cancer RenJi Hospital 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT03504163What this trial is testingPembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]Who this might be right forBladder Cancer Memorial Sloan Kettering Cancer Center 45
Post-approval studies (Phase 4)Active Not RecruitingNCT04701151What this trial is testingNORTH-REG Dwell-Time StudyWho this might be right forSide Effect of Drug Jørgen Bjerggaard Jensen 314
Testing effectiveness (Phase 2)Study completedNCT01939756What this trial is testingIntravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract SymptomsWho this might be right forSuperficial Bladder CancerLower Urinary Tract Symptoms Savino M. Di Stasi 50
Testing effectiveness (Phase 2)Study completedNCT03636256What this trial is testingEvaluation of NanoDoce® in Participants With Urothelial CarcinomaWho this might be right forBladder CancerUrothelial CarcinomaUrinary Bladder Neoplasm+6 more NanOlogy, LLC 36
Not applicableNot Yet RecruitingNCT06982690What this trial is testingAnesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized TrialWho this might be right forNMIBCTURBTBladder (Urothelial, Transitional Cell) Cancer+3 more National Taiwan University Hospital 370
Post-approval studies (Phase 4)Looking for participantsNCT05962541What this trial is testingVesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)Who this might be right forNon-muscle-invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial CarcinomaHigh Risk Non-Muscle Invasive Bladder Urothelial Carcinoma University of Roma La Sapienza 327
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07100184What this trial is testingRC48 in Combination With Radiotherapy for HER2-Expressing NMIBC PatientsWho this might be right forHER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT Peking University First Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189793What this trial is testingToripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 StudyWho this might be right forUrinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ of Bladder+1 more First Affiliated Hospital of Wenzhou Medical University 106
Testing effectiveness (Phase 2)Study completedNCT02015104What this trial is testingStudy of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCGWho this might be right forBladder Cancer National Cancer Institute (NCI) 32
Early research (Phase 1)Active Not RecruitingNCT05768347What this trial is testingIntravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBCWho this might be right forUrothelial CarcinomaNon-Invasive Bladder Urothelial Carcinoma H. Lee Moffitt Cancer Center and Research Institute 9
Testing effectiveness (Phase 2)UnknownNCT05418309What this trial is testingTilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center StudyWho this might be right forHigh-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma Tianjin Medical University Second Hospital 63
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06972615What this trial is testingIntravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive to BCG TherapyWho this might be right forNon Muscle Invasive Bladder Cancer BLATAM 37
Testing effectiveness (Phase 2)Looking for participantsNCT03317158What this trial is testingModern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the BladderWho this might be right forUrothelial CarcinomaBladder Cancer Noah Hahn, M.D. 55
Early research (Phase 1)Looking for participantsNCT05843448What this trial is testingIDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder CancerWho this might be right forHigh Risk Non-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8+1 more University of California, Davis 30